摘要
目的:测定头孢美唑和头孢西丁对产与不产超广谱β-内酰胺酶(ESBLs)菌株的体外抗菌活性。方法:收集2004年1月到2004年12月从华西医院各临床科室分离出的大肠埃希菌和肺炎克雷伯菌520株,采用K irby-Bauer琼脂扩散法进行体外药敏试验并用表型确证试验检测ESBLs。结果:筛选出产ESBLs菌226株,ESBLs阳性检出率为43.5%,其中大肠埃希菌的ESBLs检出率为45.8%,肺炎克雷伯菌的ESBLs检出率为39.6%。头孢美唑对我院ESBLs阳性菌株体外抗菌活性优于头孢西丁。结论:头霉素类抗生素可作为治疗ESBLs菌株引起的重症感染的可选药物,且对我院分离的产ESBLS大肠杆菌和肺炎克雷伯菌,头孢美唑体外活性略优于头孢西丁。
Objective ： To determine in vitro antibiotic activity of Cefmetazole and Cefoxitin against extended-spectrum beta-lactamases （ESBLs） producing and non-producing strains, Method： 520 strains of K, pneumoniae and E. coli were isolated from January 2004 to December 2004. Phenotypic confirmatory test was used to detect ESBLs; Kirby-Bauer agar diffusion method was used for drug sensitive test. Resuits：226 ESBLs strains were detected,the positve rate was 43.5% ,among which E. coli was 45.8% , and K. pneumoniae was 39.6% respectively. In vitro antimicrubial activity of Cefmetazole against Extended-Spectrum Beta-lactamases producing strains was higher than that of Cefoxitin in west china hospital. Conclusions ： cephamycins can be the alternatives for ESBLs producing strains, and in vitro antimicrobial activity of Cefrnetazole against Extended-Spectrum Beta- lactamases producing was higher than that of Cefoxitin in west china hospital.
出处
《四川生理科学杂志》
2005年第4期167-169,共3页
Sichuan Journal of Physiological Sciences
